

6 qualities to feel confident about Nintedanib

01 MORE APPROVED INDICATIONS THAN ANY OTHER ILD ANTIFIBROTIC



1st

1st antifibrotic treatment approved across 3 fibrosing interstitial lung disease (ILD) indications.¹

ANTIFIBROTIC for patients with systemic sclerosis-associated ILD (SSc-ILD), and those with chronic fibrosing ILDs with a progressive phenotype.

Nintedanib modified ILD progression by slowing forced volume capacity (FVC) decline by:

~50% | in patients with IPF in the INPULSIS® -1 and -2 and TOMORROW trials.¹⁻³

44% | in patients with SSc-ILD in the SENSICIS® trial.^{1,4}

57% | in patients with chronic fibrosing ILDs with a progressive phenotype in the INBUILD® study.^{1,5}

PROVEN & CONSISTENT SAFETY OVER THE LONG TERM



02 CONSISTENT DATA ACROSS MULTIPLE CLINICAL TRIALS

03 BENEFITS BEYOND REDUCING FVC DECLINE



33%

RISK REDUCTION of acute exacerbation or death for patients with chronic fibrosing ILDs with a progressive phenotype.^{1,5}

47%

RISK REDUCTION of acute exacerbation for patients with IPF.⁶

~2300 | patients studied across 5 clinical trials.^{1-5,+}

>80,000 | patient-years of experience.⁷

>80 | countries around the world have approved OFEV®.

5 | published *New England Journal of Medicine* papers.^{2-5,8}



04 CONFIDENCE IN NUMBERS*

05 A DISTINCTIVE MECHANISM OF ACTION



1st

1st known multitargeted tyrosine inhibitor with antifibrotic and anti-inflammatory effects that inhibit key pathways leading to pulmonary fibrosis.¹

SIMPLE AND EASY

to remember dosing schedule of a 150-mg capsule, twice a day, with no need for up-titration in the early stage of treatment.¹



06 SIMPLE, CONVENIENT DOSING

* Statistics correct as of December 2020.

+ Tallies from INPULSIS®, TOMORROW, SENSICIS®, and INBUILD® studies.

REFERENCES

- OFEV® summary of product characteristics. Boehringer Ingelheim International GmbH. January 2021.
- Richeldi L, du Bois RM, Raghu G, et al; for the INPULSIS® Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med.* 2014;380(22):2071-2082. doi:10.1056/NEJMoa1402584.
- Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med.* 2011;365(12):1079-1087. doi:10.1056/NEJMoa1103690.
- Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. *N Engl J Med.* 2019;380:2518-2528. doi:10.1056/NEJMoa1903076.
- Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med.* 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681.
- Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. *Respir Med.* 2016;113:74-79. doi:10.1016/j.rmed.2016.02.001.
- Valenzuela C, Torrisi SE, Kahn N, Quaresma M, Stowasser S, Kreuter M. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. *Respir Res.* 2020;21(1):7. doi:10.1186/s12931-019-1269-6.
- Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. *N Engl J Med.* 2018;379:1722-1731. doi:10.1056/NEJMoa1811737.